• 中國醫(yī)學(xué)科學(xué)院中國協(xié)和醫(yī)科大學(xué)北京協(xié)和醫(yī)院基本外科（北京100731）;;
  • 通訊作者： 郭俊超;

【摘要】目的 探討胰腺癌對吉西他濱化療產(chǎn)生耐藥性的相關(guān)機(jī)理。
方法 復(fù)習(xí)近年國、內(nèi)外相關(guān)文獻(xiàn)，對介導(dǎo)胰腺癌吉西他濱耐藥性的主要基因及信號(hào)通路加以綜述。
結(jié)果 癌基因c-Src與bcl-XL、NF-κB炎癥信號(hào)通路、細(xì)胞因子IL-1β及NO等與介導(dǎo)胰腺癌對吉西他濱的耐藥性密切相關(guān)； 多藥耐藥基因MDR1/PgP與胰腺癌吉西他濱耐藥的相關(guān)性仍有待研究。
結(jié)論 癌基因c-Src與bcl-XL、NF-κB炎癥信號(hào)通路等可能成為新的治療靶點(diǎn)以增加胰腺癌的化療敏感性； 介導(dǎo)胰腺癌化療耐藥的關(guān)鍵基因與中心信號(hào)通路尚有待闡明。

引用本文： 潘博,郭俊超,廖泉,趙玉沛. 吉西他濱與胰腺癌化療耐藥. 中國普外基礎(chǔ)與臨床雜志, 2005, 12(5): 530-532. doi: 復(fù)制

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer [J]. Lancet， 2004； 363(9414)∶1049.
2. 郭俊超, 趙玉沛. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學(xué)， 2002； 2(4)∶247.
3. Abrams RA. Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶3.
4. Hochster HS. Newer approaches to gemcitabinebased therapy of pancreatic cancer: fixeddoserate infusion and novel agents [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶24.
5. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes [J]. Oncology， 2002； 62(4)∶354.
6. Duxbury MS, Ito H, Zinner MJ, et al. siRNA directed against cSrc enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity [J]. J Am Coll Surg, 2004； 198(6)∶953.
7. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondriamediated apoptosis [J]. Int J Cancer, 2004； 109(2)∶182.
8. Plath T, Peters M, Detjen K, et al. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapyinduced apoptosis [J]. J Natl Cancer Inst, 2002； 94(2)∶129.
9. Fahy BN, Schlieman MG, Virudachalam S, et al. Inhibition of AKT abrogates chemotherapyinduced NFkappaB survival mechanisms: implications for therapy in pancreatic cancer [J]. J Am Coll Surg, 2004； 198(4)∶591.
10. Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death [J]. Oncogene, 2003； 22(21)∶3243.
11. Muerkoster S, Arlt A, Witt M, et al. Usage of the NFkappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003； 104(4)∶469.
12. Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin1beta [J]. Cancer Res, 2004； 64(4)∶1331.
13. Togawa A, Ito H, Kimura F, et al. Establishment of gemcitabineresistant human pancreatic cancer cells and effect of brefeldina on the resistant cell line [J]. Pancreas, 2003； 27(3)∶220.
14. 李驥. 胰腺癌和腫瘤多藥耐藥 [J]. 國外醫(yī)學(xué)外科學(xué)分冊， 2004； 31(2)∶69.
15. Zhao YP, Zhang LY, Liao Q, et al. Detection of multidrug resistant gene 1 in pancreatic cancer [J]. Hepatobiliary Pancreat Dis Int, 2004； 3(2)∶307.
16. Miller DW, Fontain M, Kolar C, et al. The expression of multidrug resistanceassociated protein (MRP) in pancreatic adenocarcinoma cell lines [J]. Cancer Lett, 1996； 107(2)∶301.
  1. 1. Li D, Xie K, Wolff R, et al. Pancreatic cancer [J]. Lancet， 2004； 363(9414)∶1049.
  2. 2. 郭俊超, 趙玉沛. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學(xué)， 2002； 2(4)∶247.
  3. 3. Abrams RA. Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶3.
  4. 4. Hochster HS. Newer approaches to gemcitabinebased therapy of pancreatic cancer: fixeddoserate infusion and novel agents [J]. Int J Radiat Oncol Biol Phys, 2003； 56(4 Suppl)∶24.
  5. 5. Shi X, Liu S, Kleeff J, et al. Acquired resistance of pancreatic cancer cells towards 5Fluorouracil and gemcitabine is associated with altered expression of apoptosisregulating genes [J]. Oncology， 2002； 62(4)∶354.
  6. 6. Duxbury MS, Ito H, Zinner MJ, et al. siRNA directed against cSrc enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity [J]. J Am Coll Surg, 2004； 198(6)∶953.
  7. 7. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondriamediated apoptosis [J]. Int J Cancer, 2004； 109(2)∶182.
  8. 8. Plath T, Peters M, Detjen K, et al. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapyinduced apoptosis [J]. J Natl Cancer Inst, 2002； 94(2)∶129.
  9. 9. Fahy BN, Schlieman MG, Virudachalam S, et al. Inhibition of AKT abrogates chemotherapyinduced NFkappaB survival mechanisms: implications for therapy in pancreatic cancer [J]. J Am Coll Surg, 2004； 198(4)∶591.
  10. 10. Arlt A, Gehrz A, Muerkoster S, et al. Role of NFkappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death [J]. Oncogene, 2003； 22(21)∶3243.
  11. 11. Muerkoster S, Arlt A, Witt M, et al. Usage of the NFkappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer [J]. Int J Cancer, 2003； 104(4)∶469.
  12. 12. Muerkoster S, Wegehenkel K, Arlt A, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin1beta [J]. Cancer Res, 2004； 64(4)∶1331.
  13. 13. Togawa A, Ito H, Kimura F, et al. Establishment of gemcitabineresistant human pancreatic cancer cells and effect of brefeldina on the resistant cell line [J]. Pancreas, 2003； 27(3)∶220.
  14. 14. 李驥. 胰腺癌和腫瘤多藥耐藥 [J]. 國外醫(yī)學(xué)外科學(xué)分冊， 2004； 31(2)∶69.
  15. 15. Zhao YP, Zhang LY, Liao Q, et al. Detection of multidrug resistant gene 1 in pancreatic cancer [J]. Hepatobiliary Pancreat Dis Int, 2004； 3(2)∶307.
  16. 16. Miller DW, Fontain M, Kolar C, et al. The expression of multidrug resistanceassociated protein (MRP) in pancreatic adenocarcinoma cell lines [J]. Cancer Lett, 1996； 107(2)∶301.